ABCL AbCellera Biologics Inc.
ABCL AbCellera Biologics Inc.
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 1 scan as of 2026-08-17 1 bull converging
POC $3.67 · VWAP $5.27 · +112.7% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 related perspective
ABCL Price Structure
Loading timeframes…
Peers
Every watchlist ABCL belongs to, members best 30-day change first — ABCL highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
@ibb
Reported the quarter ending 2026-03-31: revenue $8M, diluted EPS $-0.14, net income $-43M (SEC filing, corroborated by the desk's provider cache). Across the print the stock moved -5.5% (close before → first close after).
full note →Against street estimates
How ABCL's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about ABCL from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 1 day ago · Aug 17
- AbCellera Reports Full Year 2025 Business Results
- AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
ABCL research tape
31 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to ABCL.
Vertical: Biotech Capital Cycle — the theme is confirmed; the question is now entries
ABCL — watch above $8.45
Obesity/GLP-1 vertical: the next-gen trade is an AI-discovery + tools barbell, not a pure drug-developer bet